Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT

Bone Marrow Transplant. 2003 Jun;31(11):1065; author reply 1067. doi: 10.1038/sj.bmt.1704079.
No abstract available

Publication types

  • Clinical Trial
  • Comment
  • Comparative Study
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dexamethasone
  • Doxorubicin
  • Hematopoietic Stem Cell Mobilization / methods
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Melphalan / therapeutic use
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / therapy
  • Salvage Therapy / methods*
  • Thalidomide / therapeutic use*
  • Vincristine

Substances

  • Antineoplastic Agents
  • Thalidomide
  • Vincristine
  • Dexamethasone
  • Doxorubicin
  • Melphalan

Supplementary concepts

  • VAD protocol